Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for hemophilia.

M K Chuah1, D Collen, T VandenDriessche

  • 1Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium.

The Journal of Gene Medicine
|March 28, 2001
PubMed
Summary

Gene therapy offers a promising alternative for hemophilia A and B, showing potential for long-term correction of bleeding disorders in preclinical and early clinical studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impaired fibrinolysis and the risk for coronary heart disease.

Circulation·1996
Same author

Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.

European journal of biochemistry·1996
Same author

Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.

Circulation·1996
Same author

A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.

Thrombosis and haemostasis·1996
Same author

Role of tissue factor in embryonic blood vessel development.

Nature·1996
Same author

Effects of deletion of the carboxyl-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association.

The Journal of biological chemistry·1996

Area of Science:

  • Hematology
  • Genetics
  • Gene Therapy

Background:

  • Hemophilia A and B are X-linked recessive bleeding disorders caused by deficiencies in factor VIII (FVIII) and factor IX (FIX).
  • Current factor substitution therapy has limitations, driving research into gene therapy as an alternative treatment.
  • Gene therapy aims to provide a more permanent solution for hemophilia patients.

Purpose of the Study:

  • To review the progress and challenges in developing gene therapy for hemophilia A and B.
  • To evaluate the efficacy and safety of various gene therapy approaches in preclinical and clinical settings.
  • To highlight the potential of gene therapy for achieving a functional cure for hemophilia.

Main Methods:

  • Utilizing improved vector systems including retroviral, adenoviral, AAV, and lentiviral vectors.
  • Employing advanced gene delivery methods, both viral and non-viral.
  • Conducting preclinical studies in animal models (mice, dogs) and Phase I clinical trials in human patients.

Main Results:

  • Therapeutic levels of FVIII and FIX achieved in animal models, demonstrating long-term correction and potential cures.
  • Gene therapy approaches showed no significant adverse effects in Phase I trials, with some patients reporting reduced bleeding and detectable clotting factor activity.
  • Challenges include the induction of neutralizing antibodies and transcriptional inactivation of promoters, impacting long-term expression.

Conclusions:

  • Gene therapy has shown significant promise for treating hemophilia A and B, with encouraging preclinical and early clinical data.
  • Ongoing development of diverse strategies is crucial for overcoming current limitations and achieving a permanent cure.
  • Further research and clinical trials are necessary to fully realize the potential of gene therapy for hemophilia.

Related Experiment Videos